CPHI Barcelona

Trend report: The nexus between patient and big pharma

Collaborations between CROs and CDMOs are on the rise, empowering the newly formed entities to provide even more capabilities to their biopharma partners. But what was initially considered to be a transient industry trend is now proving itself to be a sweeping paradigm shift. So, what’s the ultimate impact on patients? Thermo Fisher Scientific’s new trend report in collaboration with CPHI explores how CRO/CDMO collaborations are moving the needle in a brighter, more patient-centric direction.

Download the report

CPHI ThermoFisher Scientific - The Nexus Between Patient and Big Pharma

Please complete the form below to request a meeting. Be sure to include your preferred topic and any specific details, and a member of our team will follow up with you shortly.

First name

Last name

Business email address

Job title

Company name

Country

State / Province

Which topic are you most interested in learning more about?

Comments

I'd like to receive marketing communications from Patheon by Thermo Fisher Scientific

I confirm that I would like to receive marketing and promotional emails about products and services from Thermo Fisher Scientific Inc. and its affiliates.

You may unsubscribe at any time by clicking on the unsubscribe link in any of the marketing communication you receive.

By submitting this form you agree to Thermo Fisher Scientific Inc. Terms of Use and Privacy Notice, including transfer of your personal data to countries outside your country of residence.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Element

Trust is the foundation of a successful partnership. It allows partners to work as one team, guided by a shared vision, with the confidence that each partner reliably do what they say they will do.

Transparent and open communication is a key element to successful project management. It requires sharing relevant information, feedback, and expectations and it encourages dialogue to address concerns and issues promptly.

Element

An effective partnership is built on mutual respect, open communication, trust, collaboration, and shared objectives, instilling confidence in customers that they will be fully supported along the development journey.

Element

Enabled through tools, technologies, and industry and scientific expertise, foresight enables teams to anticipate and mitigate challenges before they arise.

Element

Navigating the complexities of drug development and manufacturing requires passion, persistence, and unwavering dedication to achieving the shared vision of transforming patients’ lives.

Element

Every project has unique requirements, objectives, and challenges. Close and continuous collaboration is vital for understanding these distinct considerations and tailoring solutions to meet them.

Element

Real-world experience borne from decades of partnering in all aspects of drug development adds critical value to every project above and beyond the advances in sciences and technology that have transformed the industry.

Element

Scientists and subject matter experts with deep understanding of the evolving pharmaceutical landscape provide the skills and perspective to set and keep projects on the path to success.

Element

Scientific, technical, and operational knowledge acquired through deep and wide industry experience is an inimitable competitive differentiator in today’s rapidly evolving industry landscape.

Element

Keeping pace with the rapidly changing pharmaceutical industry requires unprecedented operational agility and flexibility to consistently deliver high-quality, customized solutions.

Insights and resources

Whitepaper

Transforming CDMO Partnerships Through Quality

Get an in-depth look into key indicators of CDMO quality, with tools and best practices to drive continuous improvement, strengthen collaboration, and ultimately cultivate trust.

View Infographic

Blog

What is a CDMO? Seven things to look for in a quality CDMO partner

Learn how CDMOs (contract development and manufacturing organizations) work with pharma companies, and the top considerations companies have when choosing a CDMO partner.

Read Blog

Blog

CROs vs CMOs, and CDMOs: What’s the difference between the three?

CROs, CMOs, and CDMOs all help biotechnology and pharmaceutical companies with drug development and manufacturing, but what’s the difference between the three?

Read Blog

Webinar

Optimizing the cell therapy patient journey through integrated CRO CDMO partnership

Watch this on-demand webinar for insights on how working with a single integrated CRO/CDMO partner can help ease industry challenges and provide an accelerated path from development to manufacturing, as well as the benefits that come from unified teams and infrastructure.

Watch Webinar

Infographic

CDMO Checklist to Launch Your Molecule Globally

Preparing to take your drug into the global market? You’ll need to make sure your CDMO has what it takes to successfully navigate the global regulatory space with speed, security, and supply safeguards. Use this quick list as a reference when evaluating your options.

View Infographic

Blog

Enabling a digital culture through integrated business processes

In contrast to a physical work environment, where stability and experience are key, a digital business environment focuses on innovation and connectivity. Learn more.

Read Blog

Whitepaper

The changing landscape of oncology drug development: Bringing novel lifesaving therapies to patients

Oncology is the fastest-growing, most active sector of drug development. Matching drug products to clinical and commercial needs requires scientific and technological innovation.

View Whitepaper

eBook

Protecting tomorrow: Supporting sustainability in the pharmaceutical and biotech industries

Learn how Thermo Fisher is meeting its environmental sustainability goals, and how we work in partnership with the pharma and biotech communities on shared environmental sustainability goals.

View eBook

Infographic

Preparing biologics for commercialization: Understanding Strategies to Reduce Risk and Optimize Outcomes in Drug Development

Within the drug development process, there are several steps that occur between the laboratory and final manufacture of the drug product. Different players step in during each point, so keeping a program with many moving parts on track requires planning and time-tested execution approaches.

View Infographic

Whitepaper

Advancing drug development using in silico modeling

This report provides a framework for that understanding by outlining some of the processes that stand to gain the most from computational modeling and identifying the in silico capabilities that can be used to accelerate and de-risk each phase of development.

CPHI Frankfurt 2025

The conversation starts here.

Trend report: The nexus between patient and big pharma

Find your missing element with Thermo Fisher Scientific

Insights and resources

Continuing education for the pharma industry

Follow us on social for event updates